Pharmaceutical News from PR Newswire

<< [back to news list]

    OMAHA, Neb., May 22 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC
Bulletin Board: TBIO) announces that it has appointed Antonius P. Schuh,
Ph.D. and Michael B. McNulty to its Board of Directors.

    Dr. Schuh is the Founding Chairman and Chief Executive Officer of
Sorrento Therapeutics, Inc. (STI). STI is a seed-stage biotechnology
company built on a proprietary antibody library construction technology,
the STI technology, which applies RNA transcription rather than PCR for the
amplification of variable lgG domains to yield high fidelity mAb libraries.
Prior to STI, Dr. Schuh was the Founding Chief Executive Officer and
Director of AviaraDx, Inc. AviaraDx was a molecular diagnostics laboratory
company focused on oncology testing which was acquired by bioMerieux.
Before leading AviaraDx, Dr. Schuh was Chief Executive Officer of Arcturus
Bioscience, Inc. and Sequenom, Inc.

    Mr. McNulty is currently General Manager of Diagnostics at Agilent
Technologies, Inc. Agilent Technologies Inc. is the world's premier
measurement company and a technology leader in communications, electronics,
life sciences and chemical analysis. Prior to his current position he was
Vice President of Laboratory Operations and Chief Compliance Officer of
Berkeley Heartlabs, Inc. Mr. McNulty has previously served as a board
member for Employee Health Programs, Bethesda, MD; Drug Free workplace,
plc, London, UK; ThauMDx LLC, Santa Barbara, CA; and International Cancer
Screening Laboratories, Inc. Mr. McNulty previously ran SmithKline
Beecham's Chicago based reference laboratory prior to the company's
transition to become Quest Diagnostics.

    In making this announcement, Transgenomic President and CEO, Craig
Tuttle, stated, "We are very excited to have Dr. Schuh and Mr. McNulty join
the Company's Board of Directors. Combined, they have considerable
experience in molecular diagnostics and, equally important, success in
leading and running diagnostic reference laboratories. With our continued
focus on growing Transgenomic's molecular diagnostic laboratory and
pharmacogenomic services lab, plus focusing our WAVE system and related
mutation detection technology for greater diagnostic and clinical value,
their participation on our board will provide a vital increase in
laboratory experience and guidance."

    About Transgenomic

    Transgenomic is a global biotechnology company that provides unique
products and services for automated high sensitivity genetic variation and
mutation analysis. Their offerings include systems, products, discovery and
laboratory testing services to the academic and medical research, clinical
laboratory and pharmaceutical markets in the fields of Pharmacogenomics and
personalized medicine. Specific offerings include WAVE(R) DHPLC Systems,
related consumables and assay kits, Cytogenetics automated systems, and
Transgenomic Pharmacogenomics and Reference Laboratory Services.
Transgenomic Pharmacogenomics and Laboratory Services utilize their
technology and expertise to provide a menu of mutation scanning tests for
over 700 cancer-associated genes and more than 60 validated diagnostic
tests to meet the needs of pharmaceutical and biotech companies, research
and clinical laboratories, physicians and patients. For more information
about the innovative systems, products and services offered by
Transgenomic, please visit: http://www.transgenomic.com.

    Cautionary Statements

    Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited to,
those with respect to management's current views and estimates of future
economic circumstances, industry conditions, company performance and
financial results, including the ability of the Company to grow its
involvement in the diagnostic products and services markets. The known
risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in reports to the Securities and
Exchange Commission. Any change in such factors, risks and uncertainties
may cause the actual results, events and performance to differ materially
from those referred to in such statements. Accordingly, the company claims
the protection of the safe harbor for forward-looking statements contained
in the Private Securities Litigation Reform Act of 1995 with respect to all
statements contained in this press release.